WEKO3
アイテム
Chemotherapy for biliary tract cancer: real-world experience in a single institute
https://doi.org/10.18999/nagjms.82.4.725
https://doi.org/10.18999/nagjms.82.4.7253bb25910-96b2-45aa-9e70-0d785307ddd4
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
13_Maeda-2.pdf (7.3 MB)
|
.png)
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2020-11-26 | |||||
| タイトル | ||||||
| タイトル | Chemotherapy for biliary tract cancer: real-world experience in a single institute | |||||
| 言語 | en | |||||
| 著者 |
Maeda, Osamu
× Maeda, Osamu× Ebata, Tomoki× Shimokata, Tomoya× Matsuoka, Ayumu× Inada-Inoue, Megumi× Morita, Sachi× Takano, Yuko× Urakawa, Hiroshi× Miyai, Yuki× Sugishita, Mihoko× Mitsuma, Ayako× Ando, Masahiko× Mizuno, Takashi× Nagino, Masato× Ando, Yuichi |
|||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 権利 | ||||||
| 言語 | en | |||||
| 権利情報Resource | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
| 権利情報 | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | biliary tract cancer | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | cisplatin | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | gemcitabine | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | S-1 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | cholangiocarcinoma | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The standard chemotherapy regimen for unresectable or recurrent biliary tract cancer is gemcitabine combined with cisplatin (GC). To evaluate the effectiveness and safety of chemotherapy in patients with unresectable or recurrent biliary tract cancer in the real world, we retrospectively analyzed the clinical courses of patients who underwent chemotherapy with GC from January 2015 to November 2019. Forty-eight patients underwent the GC regimen. One patient (2.1%) achieved a complete response, seven patients (14.6%) achieved a partial response, 26 patients (54.2) achieved stable disease, 11 patients (22.9%) achieved progressive disease, and 3 patients (6.3%) were not evaluable. The overall response rate was 16.7%. The median overall survival was 14.2 months (95% CI: 13.8–14.6), and the median progression-free survival was 7.7 months (95% CI: 4.2–11.2). Thirty-nine patients (81.3%) experienced grade 3 or higher severe adverse events as follows: 54.2% experienced neutropenia, 20.8% experienced anemia, 12.5% experienced thrombocytopenia and 20.8% experienced biliary tract infection. As a second-line chemotherapy, S-1 was used in seventeen patients, and stable disease was achieved in three patients (17.6%). The GC regimen for biliary tract cancer is effective and safe for unresectable or recurrent biliary tract cancer in routine clinical practice. | |||||
| 言語 | en | |||||
| 出版者 | ||||||
| 出版者 | Nagoya University Graduate School of Medicine, School of Medicine | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | departmental bulletin paper | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| ID登録 | ||||||
| ID登録 | 10.18999/nagjms.82.4.725 | |||||
| ID登録タイプ | JaLC | |||||
| 関連情報 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/824.html | |||||
| ISSN（print） | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0027-7622 | |||||
| ISSN（Online） | ||||||
| 収録物識別子タイプ | EISSN | |||||
| 収録物識別子 | 2186-3326 | |||||
| 書誌情報 |
en : Nagoya Journal of Medical Science 巻 82, 号 4, p. 725-733, 発行日 2020-11 |
|||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
